Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors? The breast, August 2013, Vol. 22(4), p.488-94.
Aapro, M., et al.
http://www.sciencedirect.com/science/article/pii/S096097761300009X
In the past few years aromatase inhibitors (AIs) have shown superior efficacy to the previous standard adjuvant endocrine therapy, tamoxifen, and are now recommended as part of current adjuvant endocrine therapy. A range of treatment strategies have been explored.
